News
FDA, Ionis Pharmaceuticals and Dawnzera
Digest more
Dawnzera is the first and so far only RNA-targeting therapy approved as a prophylactic treatment for hereditary angioedema ...
Asianet Newsable on MSN14h
Retail Traders Pile Into Ionis As Wall Street Hikes Price Targets On FDA Approval Of Swelling Disorder Therapy
BofA Securities raised its target to $64 with a ‘Buy’ rating, while Stifel lifted its target to $43 with a ‘Hold,’ both ...
Ionis has won an FDA green light for an RNA-based hereditary angioedema (HAE) treatment, Dawnzera, that can be ...
Takeda stock steadies after early dip as FDA clears Ionis' Dawnzera for hereditary angioedema, posing fresh competition to Takeda's Takhzyro.
Good morning. The Supreme Court is allowing the Trump administration to cut $783 million in research grants tied to DEI work.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback